BE2016C021I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C021I2
BE2016C021I2 BE2016C021C BE2016C021C BE2016C021I2 BE 2016C021 I2 BE2016C021 I2 BE 2016C021I2 BE 2016C021 C BE2016C021 C BE 2016C021C BE 2016C021 C BE2016C021 C BE 2016C021C BE 2016C021 I2 BE2016C021 I2 BE 2016C021I2
Authority
BE
Belgium
Application number
BE2016C021C
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of BE2016C021I2 publication Critical patent/BE2016C021I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171Demonstrated in vivo effect
BE2016C021C 2001-04-06 2016-04-26 BE2016C021I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
PCT/FR2002/001200 WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil

Publications (1)

Publication Number Publication Date
BE2016C021I2 true BE2016C021I2 (fr) 2021-03-23

Family

ID=8862055

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C021C BE2016C021I2 (fr) 2001-04-06 2016-04-26

Country Status (22)

Country Link
EP (2) EP1377660B1 (fr)
JP (1) JP4426761B2 (fr)
AU (1) AU2002307971B2 (fr)
BE (1) BE2016C021I2 (fr)
BR (1) BRPI0208896B1 (fr)
CA (1) CA2448796C (fr)
CY (2) CY1117676T1 (fr)
DK (1) DK1377660T3 (fr)
ES (2) ES2767413T3 (fr)
FR (2) FR2823222B1 (fr)
HK (2) HK1219412A1 (fr)
HU (2) HU230122B1 (fr)
IL (3) IL158204A0 (fr)
LT (1) LTC1377660I2 (fr)
LU (1) LU93048I2 (fr)
MX (1) MXPA03008998A (fr)
NL (1) NL300806I2 (fr)
PL (2) PL207584B1 (fr)
RU (1) RU2283138C2 (fr)
SI (1) SI1377660T1 (fr)
WO (1) WO2002081621A2 (fr)
ZA (1) ZA200307620B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004521867A (ja) 2000-10-27 2004-07-22 イミュノ−アールエックス, インコーポレイテッド 免疫抑制された患者のためのワクチン免疫療法
ME00491B (fr) * 2001-07-27 2011-10-10 Zoetis Services Llc Vacccin west nile
EP1572985A4 (fr) * 2002-12-13 2008-03-19 Aventis Pasteur Inc Production d'alvac sur des cellules souches aviaires
WO2004112694A2 (fr) 2003-05-23 2004-12-29 Chiron Corporation Reactifs immunogenes provenant du virus du nil occidental
WO2006029300A2 (fr) 2004-09-09 2006-03-16 Research Development Foundation Variants de flavivirus ayant une variation phenotypique et les compositions immunogeniques correspondantes
PL2529747T3 (pl) 2005-12-02 2018-08-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentuące nienatywne białka powierzchniowe i zastosowania tych wirusów
AU2009287449B2 (en) 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
EP2393921B1 (fr) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Virus chimériques de la maladie de newcastle et leurs utilisations
CA2756206A1 (fr) 2009-03-27 2010-09-30 Academia Sinica Procedes et compositions pour l'immunisation contre un virus
WO2010132867A1 (fr) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Immunothérapie par vaccin
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
MY180687A (en) 2013-03-14 2020-12-07 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
IE872455L (en) 1986-09-12 1988-03-12 Lanstrase Ltd Improved recombinant expression
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
WO1992015672A1 (fr) 1991-03-07 1992-09-17 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (fr) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
WO1996034109A1 (fr) 1995-04-25 1996-10-31 Vical Incorporated Formulations en ampoule unidose de complexes adn/lipides
EP0979101B1 (fr) 1996-07-03 2010-10-27 Merial, Inc. ADENOVIRUS CANIN 2 RECOMBINANT (ACR2) CONTENANT DE l'ADN EXOGENE
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
AU740961B2 (en) * 1997-02-28 2001-11-15 Sanofi Pasteur Biologics Co. Chimeric flavivirus vaccines
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
WO2000077043A2 (fr) 1999-06-10 2000-12-21 Merial Vaccins adn pour animaux de compagnie et de sport
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Also Published As

Publication number Publication date
CA2448796C (fr) 2012-11-20
FR16C0014I2 (fr) 2016-09-09
FR2823222B1 (fr) 2004-02-06
EP2979705B1 (fr) 2019-10-23
HK1061868A1 (zh) 2004-10-08
CY2016018I1 (el) 2016-12-14
ES2566044T3 (es) 2016-04-08
BR0208896A (pt) 2004-07-20
ZA200307620B (en) 2005-07-27
JP4426761B2 (ja) 2010-03-03
IL158204A (en) 2013-03-24
CY2016018I2 (el) 2016-12-14
BRPI0208896B1 (pt) 2016-06-07
EP1377660A2 (fr) 2004-01-07
WO2002081621A3 (fr) 2003-02-20
FR2823222A1 (fr) 2002-10-11
HUS1500047I1 (hu) 2017-03-28
HU230122B1 (hu) 2015-08-28
CA2448796A1 (fr) 2002-10-17
EP1377660B1 (fr) 2016-01-13
NL300806I2 (fr) 2016-06-09
AU2002307971B2 (en) 2008-01-17
EP2979705A1 (fr) 2016-02-03
LTC1377660I2 (lt) 2017-04-25
DK1377660T3 (en) 2016-03-29
HUP0401868A2 (hu) 2004-12-28
WO2002081621A2 (fr) 2002-10-17
PL207584B1 (pl) 2011-01-31
JP2004531521A (ja) 2004-10-14
ES2767413T3 (es) 2020-06-17
RU2283138C2 (ru) 2006-09-10
PL365210A1 (en) 2004-12-27
FR16C0014I1 (fr) 2016-05-27
LU93048I2 (fr) 2016-06-27
CY1117676T1 (el) 2016-12-14
SI1377660T1 (sl) 2016-05-31
HUP0401868A3 (en) 2011-06-28
RU2003132455A (ru) 2005-04-27
MXPA03008998A (es) 2004-10-15
PL210306B1 (pl) 2011-12-30
IL158204A0 (en) 2004-05-12
IL185263A0 (en) 2008-01-06
HK1219412A1 (zh) 2017-04-07

Similar Documents

Publication Publication Date Title
BE2022C531I2 (fr)
BE2022C502I2 (fr)
BE2022C547I2 (fr)
BE2017C055I2 (fr)
BE2017C051I2 (fr)
BE2017C032I2 (fr)
BE2016C051I2 (fr)
BE2015C046I2 (fr)
BE2014C052I2 (fr)
BE2014C036I2 (fr)
BE2014C026I2 (fr)
BE2014C004I2 (fr)
BE2014C006I2 (fr)
BE2017C050I2 (fr)
BE2011C034I2 (fr)
BE2007C047I2 (fr)
BRPI0209186B1 (fr)
BE2014C008I2 (fr)
BRPI0204884A2 (fr)
CH1379220H1 (fr)
NL300806I2 (fr)
BE2017C059I2 (fr)
JP2002224972A5 (fr)
BRPI0101486B8 (fr)
BE2012C051I2 (fr)